In the News

Share

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1740 News Items found
Seungjae Lee and Eric Lai
The Secret Life of ALAS1: How a Basic Science Discovery Could Pave the Way for Better siRNA Therapies

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.
A researcher working in an MSK lab
MSK Research Highlights, December 18, 2024

New MSK research uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.
An immunofluorescence image of an aged mouse liver
Top Cancer Research Advances at MSK in 2024

MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
Amy Speck
Top Cancer Treatment Advances at MSK in 2024

Learn about some of the most important advances in cancer treatment and clinical trials at MSK in 2024.
Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan Kettering are seen posing outdoors with the trial’s two principal investigators.
Rectal Cancer Disappears After Experimental Use of Immunotherapy, Now an FDA Designated Breakthrough Therapy

Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Article
MSK medical oncologist Komal Jhaveri.
Imlunestrant Stops Progression of ER+, HER2- Advanced Breast Cancer That Resists Standard Therapy

Read about a new treatment for people with some ER+, HER2- advanced breast cancers.
Support
Nurse practitioner Amy Devigne
MSK Program Keeps a Close Watch on Long-Term Lung Cancer Survivors

An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.
Article
Logo from the annual meeting of the American Society of Hematology.
New MSK Research on Leukemia, Lymphoma, and Myeloma Presented at 2024 Conference

Read highlights of research presented by MSK scientists at the annual ASH meeting.
MSK multiple myeloma specialist Urvy Shah
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts

Learn how eating a plant-based diet may prevent MGUS and smoldering myeloma from developing into multiple myeloma, according to MSK research.
Meryl Jacobs poses with her husband and grandkids
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With NRG1 Fusions 

The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator.